Cancer Registry Software Market By Deployment Model (On-Premise, Cloud-Based); By Type of Software (Standalone, Integrated); By Database Type (Hospital-Based, Population-Based, Specialty); By End User (Hospitals and Cancer Centers, Public Health Agencies, Pharmaceutical Companies and CROs, Academic and Research Institutions); By Geography, Segment Revenue Estimation, Forecast, 2024–2030

Introduction And Strategic Context

The Global Cancer Registry Software Market will post a steady CAGR of 9.4% , valued at around $1.25 billion in 2024 , expected to expand and reach nearly $2.15 billion by 2030 , confirms Strategic Market Research.

 

Cancer registry software has evolved from niche data collection tools into essential digital backbones for oncology care and research. These platforms track patient demographics, tumor characteristics, treatment protocols, and outcomes in a structured way. As cancer incidence keeps rising worldwide, registries have become a cornerstone for shaping public health policy, advancing precision medicine, and improving survival rates.

 

Between 2024 and 2030 , this market’s relevance will deepen. Governments are investing heavily in national cancer surveillance programs. Hospitals and cancer centers are under pressure to deliver more accurate reporting to meet regulatory mandates and secure funding. At the same time, payers and research organizations are demanding richer longitudinal data to guide reimbursement decisions and clinical trials.

 

Several macro forces are at play. The global cancer burden is climbing fast, driven by aging populations and lifestyle risk factors. Health systems are shifting toward value-based care, where outcomes tracking is non-negotiable. Technology is also moving quickly. Cloud-based registries, AI-assisted data abstraction, and interoperability standards are replacing outdated on-premise setups.

 

Key stakeholders in this ecosystem include:

• Hospitals and oncology clinics that run cancer programs and need certified software to comply with reporting standards like NAACCR and SEER.

• Public health agencies and governments deploying population-wide registries to monitor cancer trends.

• Research institutions and CROs using registry data to identify cohorts and validate treatment protocols.

• Payers and policy makers who rely on aggregated registry insights to design reimbursement models and prevention strategies.

• Software vendors and cloud service providers offering platforms that integrate seamlessly with electronic health records (EHRs) and analytics engines.

To be honest, the old days of static cancer registries are fading. Today’s systems must be dynamic, interoperable, and capable of supporting research, care delivery, and policy-making all at once. That’s why the next few years will see strong investments in modernizing these platforms.

 

Market Segmentation And Forecast Scope

The cancer registry software market breaks down along several important dimensions. Each segment reflects how hospitals, governments, and research organizations choose, implement, and fund these systems. Let’s look at how the market splits and where the strongest momentum is building.

By Deployment Model

• On-Premise solutions still have traction in hospitals worried about data control, compliance, and internal IT integration. Many legacy registries are built on local servers.

• Cloud-Based platforms are rising fast. They offer scalability, lower upfront investment, and easier remote access—critical for multi-site health systems and public health agencies.

Around 57% of total revenue in 2024 will still come from on-premise deployments, but cloud solutions are posting the fastest CAGR as more health systems modernize.

 

By Type of Software

• Standalone Cancer Registries designed for data abstraction, coding, and reporting without deep integration into broader health IT ecosystems.

• Integrated Solutions that connect with EHRs, lab systems, and clinical decision support tools to create a continuous data loop.

Integrated solutions are gaining favor because they cut duplication and improve data accuracy across departments.

 

By Database Type

• Hospital-Based Registries focus on patient care, tracking cases from diagnosis to follow-up within a single institution.

• Population-Based Registries collect data across facilities to measure incidence, mortality, and survival rates for entire regions or countries.

• Specialty Registries designed for specific cancers—like breast, colorectal, or pediatric tumors — where granular data guides research and policy.

 

By End User

• Hospitals and Cancer Centers remain the largest buyers, driven by accreditation requirements and funding incentives tied to high-quality reporting.

• Government and Public Health Agencies use registry platforms to run statewide and national cancer surveillance programs.

• Pharmaceutical Companies and CROs increasingly tap into registry datasets to identify clinical trial cohorts and understand long-term treatment outcomes.

 

By Region

• North America leads due to strong regulatory mandates (like the National Program of Cancer Registries in the U.S.) and substantial funding support.

• Europe is investing heavily in regional cancer control plans and cross-border data sharing projects.

• Asia Pacific is the fastest-growing region, thanks to rising cancer rates and government investments in digital health infrastructure.

• LAMEA lags in adoption but shows early momentum as international donors and NGOs support pilot programs.

Fastest-Growing Subsegment Cloud-based, integrated registry solutions for population-based data collection will see the strongest expansion through 2030. These systems support large-scale cancer surveillance while offering easier upgrades and analytics capabilities.

The big takeaway? As the cancer burden grows, stakeholders are shifting from static, siloed registries toward platforms that deliver interoperability, real-time analytics, and population-level insights. That’s reshaping buying criteria and budget priorities everywhere.

 

Market Trends And Innovation Landscape

Cancer registry software isn’t just about collecting records anymore. Over the last few years, it’s been evolving fast to meet tougher demands for data quality, integration, and predictive analytics. Let’s look at the trends and innovations shaping the market’s future.

Cloud Migration and SaaS Adoption Hospitals and public health agencies are steadily moving registries to the cloud. Cloud platforms reduce hardware costs, allow secure access from multiple sites, and support faster updates. Vendors are offering subscription-based models that appeal to budget-constrained health systems.

One IT director put it simply: “We just can’t afford five different on-prem registries anymore. We need a cloud backbone that does it all.”

 

Artificial Intelligence and Natural Language Processing (NLP) Manual data abstraction has been a big bottleneck. Now, AI-driven tools are automating coding and classification of unstructured data like pathology reports and clinician notes. NLP engines can scan thousands of records, flag inconsistencies, and suggest standardized codes.

This doesn’t just save time—it improves accuracy and compliance, which is critical for research and reimbursement.

 

Interoperability with EHRs and National Networks There’s a clear shift toward making registry software work seamlessly with EHR systems, lab information management systems, and national data repositories. HL7 FHIR standards are driving this integration wave, ensuring that cancer data flows across systems without manual re-entry.

To be honest, interoperability has moved from “nice to have” to “must-have.” If a platform can’t connect, it’s not even making the shortlist.

 

Advanced Analytics and Predictive Insights Many registries now include dashboards and analytics modules. These tools help cancer program directors spot trends, measure performance against benchmarks, and plan interventions. Some vendors are layering predictive models on top—estimating survival rates, recurrence risks, and treatment adherence.

 

Mobile and Remote Data Capture Especially in low-resource settings, mobile apps are emerging to help field workers collect cancer data at the point of care. This approach fills critical gaps in regions lacking robust hospital infrastructure.

 

Cybersecurity Enhancements As registries get bigger and more connected, the risks of data breaches are rising. Vendors are investing in encryption, audit trails, and compliance features to meet HIPAA, GDPR, and local privacy laws.

 

Partnerships and M&A Activity The past two years have seen a wave of collaborations between software providers, EHR vendors, and analytics firms. Some companies are acquiring smaller niche players to accelerate feature development or gain footholds in emerging markets.

A good example: A major registry vendor recently partnered with a cloud services giant to create a unified platform for cancer surveillance across multiple countries.

 

Bottom Line This market isn’t standing still. Cancer registry software is becoming a core part of digital oncology infrastructure—powered by AI, built for interoperability, and increasingly delivered as a service. The next phase will be about making these platforms smarter, faster, and easier to adopt.

 

Competitive Intelligence And Benchmarking

The cancer registry software market has no shortage of specialized players and tech-focused newcomers. Most vendors are in a race to build platforms that balance compliance, interoperability, and ease of use. Let’s look at how the main companies stack up.

Cerner Corporation Cerner offers registry solutions integrated directly into its EHR platforms. Their software focuses on streamlining case-finding, abstraction, and reporting. Cerner has strong traction in large hospital networks and academic medical centers that prefer a single vendor for clinical and registry workflows.

Strategy: Heavy investment in interoperability and automated data capture to reduce manual entry. Reach: Strong in North America, with growing presence in Europe.

 

Onco Registry (C/Net Solutions) C/Net Solutions, a division of Elekta, has built a strong niche in oncology-specific registries. Their Onco Registry software is known for compliance with NAACCR and state reporting requirements.

Strategy: Focused specialization—supporting cancer center accreditation, quality metrics, and grants reporting. Reach: Predominantly U.S., but with adoption in select international cancer programs.

 

McKesson Corporation McKesson offers cancer registry modules as part of broader oncology management solutions. Their approach integrates registry data with revenue cycle management and clinical operations.

Strategy: Position registry functions as part of end-to-end cancer program management. Reach: Large footprint in U.S. hospital systems and oncology practices.

 

IQVIA IQVIA blends registry software with advanced analytics and real-world evidence solutions. They serve pharmaceutical companies and research organizations that need robust data infrastructure for observational studies and post-market surveillance.

Strategy: Combine software with data services and research expertise. Reach: Global presence, especially strong in Europe and Asia Pacific.

 

Elsevier Elsevier’s solutions cater to cancer registries with an emphasis on data quality and coding accuracy. They’re known for tools that help registrars manage workflows efficiently.

Strategy: Differentiate on coding assistance and compliance automation. Reach: Broad footprint in academic and public health settings.

 

Conduent Incorporated Conduent has developed modular cancer registry platforms used by public health departments. They focus on population-based registries with custom reporting capabilities.

Strategy: Serve large government contracts and public health agencies. Reach: Primarily North America, with emerging interest in parts of Europe.

 

Flatiron Health Flatiron has made a name for itself by combining oncology EHRs with structured registry datasets. Their technology helps cancer centers capture real-world evidence for research and care optimization.

Strategy: Build a continuous data ecosystem that feeds both clinical care and research insights. Reach: Mostly U.S., but exploring global expansion.

 

Competitive Dynamics Here’s what’s shaping the chessboard:

• Integration is king. Hospitals don’t want disconnected registries. They prefer vendors who can plug seamlessly into EHRs and lab systems.

• Compliance expertise wins deals. Certification with NAACCR, SEER, and state reporting mandates is non-negotiable.

• Analytics is the differentiator. Platforms offering predictive insights and benchmarking dashboards are gaining an edge.

• Price matters, but performance trumps it. Cancer programs are willing to invest in systems that deliver reliable data and reduce accreditation headaches.

To be honest, this market is a classic case of consolidation meets specialization. Big EHR companies are buying or partnering with niche registry vendors, while smaller players are carving out loyal customer bases by focusing deeply on oncology workflows.

 

Regional Landscape And Adoption Outlook

Cancer registry software adoption looks different depending on where you stand. Developed markets have mature regulatory requirements and funding channels. Emerging regions are playing catch-up but showing real momentum. Let’s break this down region by region.

North America

This is by far the most established market. The U.S. has robust mandates through programs like the National Program of Cancer Registries (NPCR) and the Surveillance, Epidemiology, and End Results (SEER) Program. Nearly every state requires standardized reporting.

Hospitals here invest in advanced platforms with built-in compliance, integration with EHRs, and analytics dashboards. Canada follows a similar path, with provinces funding registry modernization efforts.

One cancer center director put it plainly: “If your registry isn’t automated and interoperable, you’re behind.”

 

Europe

Europe has a fragmented but steadily advancing landscape. The European Network of Cancer Registries (ENCR) drives harmonization across member countries, but local regulations still vary. Nations like the UK, Germany, and the Netherlands are leading adoption, tying funding incentives to high-quality reporting.

Data privacy rules under GDPR are forcing vendors to invest in encryption and compliance tools. Smaller hospitals sometimes rely on shared registry services operated by regional health authorities.

 

Asia Pacific

This region is the fastest-growing. Rising cancer incidence in China, India, and Southeast Asia is creating urgency to build national surveillance infrastructure. Governments are funding projects to modernize registries, digitize records, and train staff.

That said, adoption is uneven. In urban centers , large hospitals invest in cloud-based solutions with integrated analytics. Smaller facilities often still use paper or fragmented systems.

An oncology program lead in India shared, “We’ve got pockets of world-class systems surrounded by areas with no digital registry at all.”

 

LAMEA (Latin America, Middle East, Africa)

These markets are earlier in their development curve. In Latin America, countries like Brazil and Mexico have launched cancer control initiatives that include registry upgrades. However, funding gaps and workforce shortages slow implementation.

The Middle East is seeing pockets of investment, particularly in the Gulf states where governments are prioritizing health data infrastructure. Africa has minimal adoption outside of donor-funded pilot programs.

To be honest, LAMEA remains the biggest white space. But with the right partnerships and funding models, there’s significant upside over the next decade.

 

End-User Dynamics And Use Case

Cancer registry software ends up in very different environments. Each end user group has its own priorities, workflows, and constraints. Let’s look at how these groups are adopting and using these platforms in practice.

Hospitals and Cancer Centers

This is the biggest customer segment by far. Hospitals use registry software to comply with accreditation requirements from organizations like the Commission on Cancer (CoC) and to secure funding tied to quality reporting.

They want systems that:

• Integrate seamlessly with EHRs and lab systems.

• Automate abstraction from pathology reports.

• Produce standardized outputs for NAACCR and state reporting.

• Offer dashboards to monitor performance indicators.

One oncology director summed it up: “If the software can’t prove compliance and save us time, we can’t justify the budget.”

 

Public Health Agencies

National and regional health departments buy cancer registry platforms to track population trends, identify disparities, and support prevention policies.

Their focus is on:

• Population-based data collection.

• Multi-site access and centralized reporting.

• Strict privacy and security controls.

 

Pharmaceutical Companies and CROs

Pharma and contract research organizations use registry data to:

• Identify eligible patients for clinical trials.

• Track long-term treatment outcomes.

• Generate real-world evidence for regulatory submissions.

These buyers care about data completeness, standardization, and the ability to integrate with research databases.

 

Academic and Research Institutions

Universities and research hospitals leverage registries for epidemiological studies and grant-funded projects. They often prefer configurable systems that can support novel data collection elements beyond mandatory fields.

Use Case Highlight A large regional cancer center in the Midwest U.S. was facing delays in submitting annual CoC compliance reports. Staff were spending hundreds of hours manually abstracting and coding data from disparate systems. In 2023, the center adopted a cloud-based integrated registry platform with AI-powered data abstraction. Within the first year, abstraction times fell by nearly 40%. Compliance rates improved, and the center received additional quality funding. The director noted that the time savings alone justified the investment.

 

Bottom Line Different end users see value through different lenses. Hospitals want compliance and efficiency. Public agencies need population-level visibility. Pharma is looking for research-grade data. But the universal theme is clear: registries are evolving into essential tools that blend clinical care, surveillance, and research.

 

Recent Developments + Opportunities & Restraints

Recent Developments (Last 2 Years)

• Cerner Corporation launched an enhanced cloud-based oncology registry module in 2024. It integrates AI-assisted abstraction and new interoperability features supporting HL7 FHIR standards.

• Flatiron Health expanded partnerships with major cancer centers in Europe to create real-world evidence networks linking registry data and EHRs.

• IQVIA introduced an advanced analytics engine for registry datasets, offering predictive modeling and visualization tools tailored for pharma clients.

• Conduent secured new public health contracts in several U.S. states to modernize population-based cancer registries with cloud platforms.

• Elsevier released updated registry workflow software with embedded natural language processing to improve coding accuracy.

 

Opportunities

• Cloud Adoption Acceleration Hospitals and governments are actively replacing legacy registries. Vendors offering SaaS platforms with flexible pricing are well-positioned to capture this wave.

• AI Integration for Data Abstraction Artificial intelligence and NLP can cut manual workload and improve accuracy. This is a clear differentiator, especially in large cancer centers processing thousands of records annually.

• Emerging Market Expansion Asia Pacific and parts of Latin America are funding national cancer control programs. Vendors who can deliver affordable, scalable solutions will find untapped demand.

 

Restraints

• High Upfront Costs Even with subscription models, implementation expenses—training, migration, customization—can be significant, especially for mid-sized hospitals.

• Data Privacy and Security Challenges Stricter regulations like GDPR in Europe and evolving U.S. state laws force vendors to maintain robust security protocols, which can slow deployments and increase costs.

To be honest, the growth potential here is strong, but vendors have to solve two big puzzles: making their platforms affordable and ensuring data security is bulletproof.
 

7.1. Report Coverage Table

Report Attribute	Details
Forecast Period	2024 – 2030
Market Size Value in 2024	USD 1.25 Billion
Revenue Forecast in 2030	USD 2.15 Billion
Overall Growth Rate	CAGR of 9.4% (2024 – 2030)
Base Year for Estimation	2024
Historical Data	2019 – 2023
Unit	USD Million, CAGR (2024 – 2030)
Segmentation	By Deployment Model, By Type of Software, By Database Type, By End User, By Geography
By Deployment Model	On-Premise, Cloud-Based
By Type of Software	Standalone, Integrated
By Database Type	Hospital-Based, Population-Based, Specialty
By End User	Hospitals and Cancer Centers, Public Health Agencies, Pharmaceutical Companies and CROs, Academic and Research Institutions
Customization Option	Available Upon Request